BioActor develops clinically evaluated polyphenol extracts from edible plants and fruits.
Ingredients supplier Solabia Group (Paris) has acquired a majority stake in BioActor B.V. (Maastricht, the Netherlands), which develops clinically evaluated polyphenol extracts from edible plants and fruits.
A press release states, “Solabia is already present in the nutrition segment through original ingredients recognized for their health benefits, including Algatech’s microalgae-derived active ingredients. This strategic investment will allow Solabia to benefit from a wider range of ingredients and from BioActor’s expertise, strengthening its nutrition division positioning [in] this fast-growing market as customers increasingly look for high-quality active ingredients that combine naturality with proof of efficacy.”
BioActor will continue to focus on R&D and product development, with the companies stating that “BioActor will become a center of excellence for innovation and clinical research within Solabia’s nutrition division…”
Judge in CRN’s complaint against NY denies the State’s motion to dismiss
May 14th 2024New York State's motion to dismiss CRN's lawsuit against the law banning the sale of weight management and muscle-building supplements to minors has been partially denied, allowing CRN to proceed with its First Amendment Claim.